中国新药与临床杂志 Chinese Journal of New Drugs and Clinical Remedies ISSN 1007-7669,CN 31-17nemia：enarodustat
LI Geng，BAI Qiu-jiang，ZHU Hui-dong (Affiliated Taikang Xianlin Drumtower Hospital, Medical College of Nanjing University，Jiangsu Nanjing 210046, China) [KEY WORDS] enarodustat；renal insufficiency, chronic；anemia；clinical study [ABSTRACT] Anemia has a high incidence rate in chronic kidney disease (CKD) population, and the severity of anemia gradually increases with the decline of renal function. Enarodustat is another oral hypoxia-inducible factor prolyl hydroxylase inhibitor followed roxadustat. It was approved in Japan for the treatment of renal anemia on September 25, 2020. The clinical trials have shown that enarodustat is safe and effective in the treatment of renal anemia with mild adverse reactions. The effective dose is only 1 / 10 ~ 1 / 5 of roxadustat, and it can protect the kidney and reduce cholesterol.
